Piper Sandler analyst Edward Tenthoff downgraded iTeos Therapeutics (ITOS) to Neutral from Overweight with a price target of $10.05, down from $12, after the company entered into am merger agreement whereby Concentra Biosciences will acquire iTeos for $10.047 in cash per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- Vor Bio appoints Cumbo, Detheux to board of directors
- iTeos Therapeutics Announces Merger with Concentra Biosciences
- iTeos to be acquired by Concentra for $10.047 per share in cash plus CVR
- GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment
- GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab